Tadalafil + Placebo + Finasteride

Phase 3Completed
0 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Benign Prostatic Hyperplasia

Conditions

Benign Prostatic Hyperplasia, Enlarged Prostate

Trial Timeline

Sep 1, 2010 → May 1, 2012

About Tadalafil + Placebo + Finasteride

Tadalafil + Placebo + Finasteride is a phase 3 stage product being developed by Eli Lilly for Benign Prostatic Hyperplasia. The current trial status is completed. This product is registered under clinical trial identifier NCT01139762. Target conditions include Benign Prostatic Hyperplasia, Enlarged Prostate.

What happened to similar drugs?

10 of 20 similar drugs in Benign Prostatic Hyperplasia were approved

Approved (10) Terminated (2) Active (8)
Tamsulosin OCASAstellas PharmaApproved
Tamsulosin OCAS + PlaceboAstellas PharmaApproved
Tamsulosin + Finasteride + PlaceboAstellas PharmaApproved
ErtapenemMerckApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01139762Phase 3Completed

Competing Products

20 competing products in Benign Prostatic Hyperplasia

See all competitors